MiMedx Group, Inc. (MDXG)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.57+3.16%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MDXG
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 0.5% |
| Our one-year growth estimate | diamond | -5.5% |
Growth built into the price is above our model estimate.
The price assumes 6.0 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
MDXG — earnings miss
Dated 2026-07-29
Results of Operations and Financial Condition On July 29, 2026, MiMedx Group, Inc. (the “ Company ”), issued a press release (the “ Earnings Press Release ”) announcing its results for the second quarter of 2026. A copy of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information is furnished pursuant to Item 2.02, “Results of Operations and Financial Condition”, including Exhibit 99.1 attached hereto, and shall not be dee…
Why it matters: If revenue growth speeds up, it could signal a positive shift for MiMedx and the sector.
Supportive ifHealth Care sector revenue growth moves back toward 10% year over year.
Worry ifRevenue growth is still under 10%. This shows it is slowing down.
Why it matters: Getting to breakeven is vital for MiMedx. It helps regain investor trust and stability.
Supportive ifAdjusted EBITDA for 2026 shows progress and gets closer to breakeven.
Worry ifAdjusted EBITDA for 2026 is still very low.
Why it matters: Cost savings from restructuring are key for making money again.
Supportive ifOperating expenses decrease by at least $10 million in Q2 2026.
Worry ifOperating expenses do not decrease or increase in Q2 2026.
Why it matters: Good cost management is key for MiMedx to make money again.
Supportive ifManagement reports achieving at least $10 million in cost savings by Q4 2026.
Worry ifCost savings reported are less than $5 million by Q4 2026.
Why it matters: Recovery in the wound segment is key for the company’s growth.
Watch forWound sales grow sequentially by at least 10% in Q3 2026.
Also watch forWound sales decline further in Q3 2026.
Why it matters: Getting these synergies would make more money and support the merger's purpose.
Supportive ifManagement says they have saved $20 million in costs after the merger.
Worry ifManagement says cost savings are not happening as planned.
Why it matters: Breakeven in adjusted EBITDA matters for financial health. It shows the company is doing better.
Supportive ifThe company says adjusted EBITDA is near breakeven in Q2.
Worry ifAdjusted EBITDA is still very negative in Q2.
Why it matters: If Wound Care sales improve, it means the market is adjusting to new Medicare rules.
Supportive ifWound Care sales are up compared to the previous quarter.
Worry ifWound Care sales are down compared to the previous quarter.
Why it matters: Closing this deal is key to expanding MiMedx's surgical revenue and market presence.
Supportive ifThe acquisition will close by the end of 2026. All approvals are secured.
Worry ifThe deal might not go through. Shareholders or regulators could cause problems.
Why it matters: If surgery grows a lot, it will prove the Sanara deal works.
Supportive ifSurgical revenue grew over 15% in Q3 compared to last year.
Worry ifSurgical revenue growth in Q3 is below 10% year-over-year.
Why it matters: If it drops below this level, the Wound business will face ongoing problems. This is due to issues with reimbursements.
Worry ifQ2 2026 net sales reported below $60 million.
Less concerning ifQ2 2026 net sales reported above $60 million.
Why it matters: The COO leaving may impact how well the company runs and manages costs. Keep an eye on this.
Worry ifOperational metrics get worse or costs go up after the COO leaves.
Less concerning ifOperational metrics improve. This shows strength even with changes in leadership.
Why it matters: Earnings results will show how the company is doing now and in the future.
Watch forEarnings report shows revenue growth getting better than in past quarters.
Also watch forEarnings report shows lower revenue or profits than in past quarters.
Why it matters: Managing costs well is important for making more money. Progress shows better financial health.
Supportive ifManagement says operating costs fell by at least 10% in Q2.
Worry ifOperating expenses stay the same or go up. This shows cost management is not working.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$162 on $10,000 · ±1.6% | How much price usually moves either way. |
| Bad day | $400 loss on $10,000 · 4.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,124 loss on $10,000 · 61.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.